A Phase 2a Study of BIIB074 in the Treatment of Erythromelalgia
Completed · Phase 2 · Has a placebo group
Conditions studied: Primary Inherited Erythromelalgia
In brief
The primary objective of the study is to investigate the efficacy of repeat oral dosing of BIIB074 on paroxysmal pain in participants with Primary Inherited Erythromelalgia (EM). The secondary objective of the study is to investigate the efficacy of repeat oral dosing of BIIB074 on varying additional aspects of pain in participants with EM; and to investigate the safety and tolerability of repeat oral dosing of BIIB074 in participants with EM.
Key facts
- Study ID
- NCT02917187
- Run by
- Biogen
- People needed
- 8
- Starts
- 2016-09-09
- Expected to finish
- 2017-01-05
- Last updated by the study team
- 2018-01-10
Who can join
Age: 18 and older. Sex: any. Healthy volunteers: not accepted.
Where it is running
- Research Site — Birmingham, Alabama, United States
- Research SIte — New London, Connecticut, United States
- Research Site — Philadelphia, Pennsylvania, United States
- Research Site — Plano, Texas, United States
- Research Site — Morgantown, West Virginia, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.